CHAD

Across TCGA pan-cancer cohorts, CHAD Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CHAD data layer compared with 23 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher CHAD Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CHAD expression acts as an unfavorable survival marker.

DLBC, UCEC, and PRAD are the cancer types where CHAD Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	DFS	Median	II,III,IV	0.022	0.837	<.001	12	view →
UCEC	OS	Median	IV	0.225	0.772	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
COAD	DFS	Median	All	0.170	0.504	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CHAD–DLBC (DFS)

Open the DLBC breakdown →